DENGUE VIRUS-SPECIFIC HUMAN CD4+ T-LYMPHOCYTE RESPONSES IN A RECIPIENT OF AN EXPERIMENTAL LIVE-ATTENUATED DENGUE VIRUS TYPE-1 VACCINE - BULK CULTURE PROLIFERATION, CLONAL ANALYSIS, AND PRECURSOR FREQUENCY DETERMINATION

被引:54
作者
GREEN, S
KURANE, I
EDELMAN, R
TACKET, CO
ECKELS, KH
VAUGHN, DW
HOKE, CH
ENNIS, FA
机构
[1] UNIV MASSACHUSETTS,MED CTR,DEPT MED,DIV DIS & IMMUNOL,WORCESTER,MA 01605
[2] UNIV MARYLAND,CTR VACCINE DEV,BALTIMORE,MD 21201
[3] WALTER REED ARMY INST RES,DEPT VIRAL DIS,WASHINGTON,DC 20307
[4] WALTER REED ARMY INST RES,DEPT BIOL RES,WASHINGTON,DC 20307
关键词
D O I
10.1128/JVI.67.10.5962-5967.1993
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We analyzed the CD4+ T-lymphocyte responses to dengue, West Nile, and yellow fever viruses 4 months after immunization of a volunteer with an experimental live-attenuated dengue virus type 1 vaccine (DEN-1 45AZ51. We examined bulk culture proliferation to noninfectious antigens, determined the precursor frequency of specific CD4+ T cells by limiting dilution, and established and analyzed CD4+ T-cell clones. Bulk culture proliferation was predominantly dengue virus type 1 specific with a lesser degree of cross-reactive responses to other dengue virus serotypes, West Nile virus, and yellow fever virus. Precursor frequency determination by limiting dilution in the presence of noninfectious dengue virus antigens revealed a frequency of antigen-reactive cells of 1 in 1,686 peripheral blood mononuclear cells (PBMC) for dengue virus type 1, 1 in 9,870 PBMC for dengue virus type 3, 1 in 14,053 PBMC for dengue virus type 2, and 1 in 17,690 PBMC for dengue virus type 4. Seventeen CD4+ T-cell clones were then established by using infectious dengue virus type 1 as antigen. Two patterns of dengue virus specificity were found in these clones. Thirteen clones were dengue virus type 1 specific, and four clones recognized both dengue virus types 1 and 3. Analysis of human leukocyte antigen (HLA) restriction revealed that five clones are HLA-DRw52 restricted, one clone is HLA-DP3 restricted, and one clone is HLA-DP4 restricted. These results indicate that in this individual, the CD4+ T-lymphocyte responses to immunization with live-attenuated dengue virus type 1 vaccine are predominantly serotype specific and suggest that a multivalent vaccine may be necessary to elicit strong serotype-cross-reactive CD4+ T-lymphocyte responses in such individuals.
引用
收藏
页码:5962 / 5967
页数:6
相关论文
共 18 条
  • [1] HUMAN CYTOMEGALOVIRUS-SPECIFIC CYTO-TOXIC T-CELLS - THEIR PRECURSOR FREQUENCY AND STAGE SPECIFICITY
    BORYSIEWICZ, LK
    GRAHAM, S
    HICKLING, JK
    MASON, PD
    SISSONS, JGP
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1988, 18 (02) : 269 - 275
  • [2] BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
  • [3] BRETT SJ, 1987, CLIN EXP IMMUNOL, V68, P510
  • [4] DENGUE VIRUS-SPECIFIC CROSS-REACTIVE CD8+ HUMAN CYTO-TOXIC T-LYMPHOCYTES
    BUKOWSKI, JF
    KURANE, I
    LAI, CJ
    BRAY, M
    FALGOUT, B
    ENNIS, FA
    [J]. JOURNAL OF VIROLOGY, 1989, 63 (12) : 5086 - 5091
  • [5] HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268
  • [6] DENGUE AND DENGUE HEMORRHAGIC-FEVER
    HAYES, EB
    GUBLER, DJ
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1992, 11 (04) : 311 - 317
  • [7] HOFFENBACH A, 1989, J IMMUNOL, V142, P452
  • [8] DENGUE VIRUS-SPECIFIC HUMAN T-CELL CLONES - SEROTYPE CROSSREACTIVE PROLIFERATION, INTERFERON GAMMA-PRODUCTION, AND CYTO-TOXIC ACTIVITY
    KURANE, I
    MEAGER, A
    ENNIS, FA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (03) : 763 - 775
  • [9] LYSIS OF DENGUE VIRUS-INFECTED CELLS BY NATURAL CELL-MEDIATED CYTO-TOXICITY AND ANTIBODY-DEPENDENT CELL-MEDIATED CYTO-TOXICITY
    KURANE, I
    HEBBLEWAITE, D
    BRANDT, WE
    ENNIS, FA
    [J]. JOURNAL OF VIROLOGY, 1984, 52 (01) : 223 - 230
  • [10] HUMAN T-CELL RESPONSES TO DENGUE VIRUS-ANTIGENS - PROLIFERATIVE RESPONSES AND INTERFERON GAMMA PRODUCTION
    KURANE, I
    INNIS, BL
    NISALAK, A
    HOKE, C
    NIMMANNITYA, S
    MEAGER, A
    ENNIS, FA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (02) : 506 - 513